Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Tipo de estudio
Intervalo de año de publicación
1.
Dtsch Med Wochenschr ; 147(9): 558-563, 2022 04.
Artículo en Alemán | MEDLINE | ID: mdl-35468637

RESUMEN

BACKGROUND: Neutralizing monoclonal antibodies (mAB) against SARS-CoV-2 reduce the severity of COVID-19 in patients with risk factors. Early administration at the onset of infection is critical for their efficacy. At this early stage of the disease, family physicians are often the first help for patients and thus central to the further course of the disease. To date, however, mAB have only rarely been used in general practice. The purpose of this case series is to demonstrate that the administration of mAB is safely feasible in the primary care setting. CASE REPORT: We report seven cases at risk for severe COVID-19. Two of them were not vaccinated, five had drug induced immunosuppression, and one patient was at high risk because of trisomy-21. All patients were successfully treated with the mAB Sotrovimab in a GP's practice in January/ February 2022. Two patients were treated making a house call. Based on the cases, clinical information and a hands-on handling of this therapy are described. CONCLUSIONS: Neutralizing mAB can be administered safely and with manageable effort in primary care setting and can help prevent a severe course and hospitalization in patients with COVID-19 and risk factors.


Asunto(s)
Antineoplásicos Inmunológicos , COVID-19 , Medicina General , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Anticuerpos Neutralizantes , Anticuerpos Antivirales , Humanos , Glicoproteínas de Membrana , Pruebas de Neutralización , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus , Proteínas del Envoltorio Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA